SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 52-Week High – Should You Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $9.11 and last traded at $9.0450, with a volume of 2398218 shares traded. The stock had previously closed at $8.58.

Analyst Ratings Changes

SLS has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. Maxim Group lifted their price target on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, SELLAS Life Sciences Group currently has a consensus rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Trading Up 5.6%

The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -39.42 and a beta of 2.24. The firm has a 50 day moving average price of $5.45 and a 200-day moving average price of $4.09.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Institutional Trading of SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dagco Inc. purchased a new stake in SELLAS Life Sciences Group during the 4th quarter worth about $2,177,000. Everhart Financial Group Inc. purchased a new stake in SELLAS Life Sciences Group during the 3rd quarter worth about $533,000. Anson Funds Management LP grew its position in shares of SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after purchasing an additional 5,757,938 shares during the period. NORTHSTAR ASSET MANAGEMENT Co increased its stake in SELLAS Life Sciences Group by 24.0% in the fourth quarter. NORTHSTAR ASSET MANAGEMENT Co now owns 50,000 shares of the company’s stock valued at $188,000 after purchasing an additional 9,680 shares during the last quarter. Finally, Visionary Horizons LLC acquired a new position in SELLAS Life Sciences Group in the fourth quarter valued at $136,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.